CLINICAL TRIALS PROFILE FOR AMLODIPINE BESYLATE; OLMESARTAN MEDOXOMIL
✉ Email this page to a colleague
All Clinical Trials for amlodipine besylate; olmesartan medoxomil
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00311155 ↗ | Olmesartan and an add-on Treatment in Patients With Mild to Moderate Hypertension | Completed | Sankyo Pharma Gmbh | Phase 4 | 2006-03-01 | This study is to assess the safety and efficacy of an add-on treatment algorithm with olmesartan, hydrochlorothiazide and amlodipine in patients with mild to moderate hypertension. |
| NCT00649389 ↗ | Safety and Efficacy Study of a Triple Combination Therapy in Subjects With Hypertension | Completed | Daiichi Sankyo Inc. | Phase 3 | 2008-05-01 | To determine the effectiveness of four different strength combinations of three approved anti-hypertension therapies (olmesartan medoxomil, amlodipine, and hydrochlorothiazide) for lowering blood pressure. |
| NCT00649389 ↗ | Safety and Efficacy Study of a Triple Combination Therapy in Subjects With Hypertension | Completed | Daiichi Sankyo, Inc. | Phase 3 | 2008-05-01 | To determine the effectiveness of four different strength combinations of three approved anti-hypertension therapies (olmesartan medoxomil, amlodipine, and hydrochlorothiazide) for lowering blood pressure. |
| NCT00890591 ↗ | Efficacy and Safety of Olmesartan Medoxomil in Stage 1 and 2 Essential Hypertension | Completed | Daiichi Sankyo Inc. | Phase 4 | 2006-08-01 | In patients naive to treatment or after a 2-week washout period for patients whose treatment was ineffective, the use of olmesartan was assessed in a 4-phase treatment scheme: monotherapy, addition of hydrochlorothiazide (2 phases), addition of amlodipine. |
| NCT00890591 ↗ | Efficacy and Safety of Olmesartan Medoxomil in Stage 1 and 2 Essential Hypertension | Completed | Daiichi Sankyo, Inc. | Phase 4 | 2006-08-01 | In patients naive to treatment or after a 2-week washout period for patients whose treatment was ineffective, the use of olmesartan was assessed in a 4-phase treatment scheme: monotherapy, addition of hydrochlorothiazide (2 phases), addition of amlodipine. |
| NCT00923091 ↗ | Parallel-Group Comparison of Olmesartan (OLM), Amlodipine (AML) and Hydrochlorothiazid (HCTZ) in Hypertension | Completed | Daiichi Sankyo Inc. | Phase 3 | 2009-06-01 | This study is to determine the change in blood pressure from the administration of Olmesartan/Amlodipine/Hydrochlorothiazide triple combinations compared to dual combinations with Olmesartan/Amlodipine. |
| NCT00923091 ↗ | Parallel-Group Comparison of Olmesartan (OLM), Amlodipine (AML) and Hydrochlorothiazid (HCTZ) in Hypertension | Completed | Daiichi Sankyo, Inc. | Phase 3 | 2009-06-01 | This study is to determine the change in blood pressure from the administration of Olmesartan/Amlodipine/Hydrochlorothiazide triple combinations compared to dual combinations with Olmesartan/Amlodipine. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for amlodipine besylate; olmesartan medoxomil
Condition Name
Clinical Trial Locations for amlodipine besylate; olmesartan medoxomil
Trials by Country
Clinical Trial Progress for amlodipine besylate; olmesartan medoxomil
Clinical Trial Phase
Clinical Trial Sponsors for amlodipine besylate; olmesartan medoxomil
Sponsor Name
